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1. Introduction   
From the immunological point of view, the infections produced by intracellular bacteria 
have several particular features: 
1. protection against intracellular bacteria is mediated by T cells, which are interacting, 
not directly with the pathogen, but with the infected cell surface; antibodies exhibit a 
minor effect on the immune protection against intracellular infections; 
2. infections by intracellular bacteria is accompanied by delayed hypersensitivity reactions 
that occur after the local administration of soluble antigens, mediated by T cells, whose 
effectors are macrophages; 
3. tissular reactions to anti- intracellular bacteria are granulomatous in nature, both the 
protective responses and pathology being caused by them. Breaking granuloma favors 
pathogen dissemination and extension of lesions; 
4. intracellular bacteria are expressing little or no toxic effects to the host cell, and 
pathology results from the activation of the immune response, mediated primarily by T 
lymphocytes. In contrast, extracellular bacteria secrete extracellular toxins, some of 
them being extremely potent and producing direct tissue damage; 
5. intracellular bacteria are well adapted for coexisting with the host cell for long periods, 
by maintaining a balance between the persistent infection and the protective immunity 
mechanisms, resulting in a long incubation period and the development of a chronic 
infectious process. The infection per se is distinct from the pathological process. In 
contrast, extracellular bacteria cause acute infections, which are triggered soon after 
infection and ending after the immune response reaches an optimal intensity. 
Some pathogenic bacteria such M. tuberculosis, M. bovis, M. leprae, S. enterica, Brucella sp., L. 
monocytogenes, Francisella tularensis, are facultatively intracellular, passing through a 
intracellular phase during their infectious cycle, without being strictly dependent on the 
cellular environment. They could infect primarily monocytes, but also other cells. In 
contrast, strictly intracellular parasitic bacteria (Chlamydia, Rickettsia) do not survive in the 







2. Life cycle of clamydiales  
Chlamydiae are Gram-negative intracellular bacteria found in a wide variety of hosts. 
Chlamydia species infectious to humans are: Chlamydophila psittaci, Chlamydia trachomatis 
(biovar lymphogranuloma venereum - LGV and trachoma) and Chlamydia pneumoniae. 
Differentiation is based on their antigenic composition, susceptibility to sulfonamides and 
pathogenesis. Chlamydia pecorum is infectious to animals, but not to humans. Chlamydophila 
psittaci is parasitic on birds and mammals, and much more rarely to cold-blood vertebrates 
and humans. Chlamydia trachomatis is parasitic for mice and humans. In mammals and birds, 
both species produce eye conjunctiva, urogenital, respiratory and digestive tract infections 
and possibly at other sites (Barnes, 1990). 
Chlamydia species have similar morphology and a common development cycle. By adapting 
to the intracellular compartment, chlamydiae lost a lot of the energy producing metabolic 
ways and the ability to produce ATP, but preserved some major metabolic activities, such 
are: glycolysis, respiration, pentoses biosynthesis. Development of intracellular chlamydiae 
depends on ATP and other high energy compounds derived from the host cell. Chlamydiae 
possess the enzymatic systems required for DNA, RNA and proteins synthesis, but they use 
many of the host cell precursors (nucleotides, amino acids, nutrients, vitamins, various 
cofactors) (Madigan et al., 1997). 
In terms of structure, there were identified two chlamydia types: the infectious, 
nonreplicating elementary body (EB) and the noninfectious, but actively replicating 
reticulate body (RB), which are alternating in the development of the infectious cycle. The 
two morphologically distinct forms - the EBs and RBs - are representing adaptations to the 
extracellular environment and respectively to the intracellular one. The infectious particle, 
stable in the extracellular environment is a small cell, called the elementary body. They enter 
the host cell, multiply and disseminate in the extracellular environment. To complete these 
steps, chlamydiae undergo a developmental cycle that includes forms with alternating 
morphology and function.  
Chlamydia cell wall is similar to the Gram-negative bacteria, with increased lipid content, but 
does not contain peptidoglycan (Hatch, 1996) (Fig. 1). Pentapeptidic similar components 
may be present, because their growth and division is altered in the presence of ǃ-lactam 
antibiotics. 
 
Fig. 1. Structure of the Chlamydia cell wall (membrane Momp major out membrane protein, 
CRP, cysteine-rich protein)  
www.intechopen.com
 
Host Immune Response to Chlamydia Infection 
 
77 
The outer membrane of Chlamydia pneumoniae is composed of lipopolysaccharides (LPS) and 
heat-shock proteins (HSP) that are genus specific (Matsumoto et al., 1991, Shirai et al., 2000). 
The bacterial family of Chlamydiaceae comprises a group of obligate intracellular pathogens 
which harbour a highly truncated LPS, being composed of KDO (2-keto-3-deoxyoctonate) 
units only. In all chlamydial species, the linear trisaccharide a-KDO-(2 - 8)-a-KDO-(2 - 4)-a-
Kdo has been found, thereby constituting a family specific antigen. Antibodies raised 
against these neoglycoconjugates displayed a wide range of specificities and affinities.  
Several major outer membrane proteins (MOMP) identified are detectable by monoclonal 
antibodies and are species specific (Matsumoto et al., 1991, Shirai et al., 2000). Under these 
persistence-inducing conditions, the chlamydial Hsp60 appears to be highly upregulated. 
Chlamydial Hsp60 has proinflammatory effects by directly activating mononuclear 
leukocytes, which are mediating the inflammatory response. Chlamydial persistence is 
characterized by morphologically aberrant RBs that do not undergo cytokinesis, considered 
a third chlamydial type, called the noninfectious, nonreplicating persistent body (PB). 
Persistent Chlamydia, however, re-enter the productive life cycle upon removal of the stress 
factor. 
The infectious chlamydial form is the EB, which is adhering to the target cell membrane and 
initiates penetration. Elementary body is small, dense, with a rigid cell wall, given by the 
multiple SS bonds and to two other major outer membrane proteins (CRPs): a wall protein 
of 60 kDa and the outer membrane lipoprotein of 12 kDa. EB is resistant to environmental 
factors favouring survival in the extracellular environment after cell lysis and switching 
from one cell or one host to another. EB is not dividing, is metabolically inert, but has high 
affinity for epithelial cells. Its role is to spread the infection from one cell to another. Its 
membrane contains heparan-sulphate (proteoglycan), a ligand, through which they are 
attached to the microvilli and subsequently embedded in clatrin vesicles by receptors 
mediated endocytosis. Chlamydiae remain in the intracellular vacuole with non acid pH 
and avoid the fusion of the phagocytic vesicle with the lysosomes by unknown mechanisms. 
Inside the large vacuole, chlamydiae are redistributed from the cell periphery to the nucleus 
periphery by a mechanism dependent on actin F. The EB undergoes morphological changes 
and reorganization in the RB which is larger, metabolically active, and divides repeatedly by 
binary fission and becomes visible as a microcolony known as chlamydial inclusion. RB 
contains 4 times more RNA than DNA and RNA, while the EB contains equal proportions of 
RNA and DNA. 
The EB - RB conversion requires the alteration of the outer membrane structure by the 
cleavage of SS bonds. Reduction of SS bonds leads to increased membrane fluidity, 
increased permeability, favours the nutrients transport from the host cell and the intiation of 
metabolic activity. After a period of growth and division, EB is reorganized; it condenses 
and forms numerous EBs. Development cycle is complete, with the host cell lysis and 
subsequent release of EB which are initiating a new infection cycle (fig. 2). The complete 
development cycles, when studied in cell cultures, is taking 47-72 hours and vary depending 
on the strain, the host cell and the environmental conditions (Campbell & Kuo, 2004).  
The pathological processes due to chlamydial infection appear to be mediated by the 
immune reactivity. The host immune response stimulated by repeated episodes of infection 






changes. Persistence of infection has been shown in different cell cultures being associated 
with PBs, which remain viable but not replicating, suggesting an innate ability of 
chlamydiae to persist intracellularly, and the mechanism by which they induce a 
pathological process. The factors favouring the persistence are unknown. 
 
Fig. 2. Life cycle to Chlamydia pneumoniae  
Chlamydiae, and other intracellular pathogens, are circumventing the normal mechanisms 
of host cell defences. Endocitated chlamydiae are sequestered in the host cell membrane 
derived phagosome. The key event that allows the survival of the infectious agent in the 
host cell is the inhibition of phagosome–lisosome fusion. Persistently infected cultures are 
less sensitive to rifampicin and clortetracycline, which suggests that chlamydiae DNA 
transcription and translation continues in the persistent forms. 
In vitro, chlamydia can invade host cells deficient in nutrients and after the entry they adopt 
a dormant, non-infectious, but viable state. The persistence of the non-replicative stage is 
reversible. By adding for example, L-isoleucine, an essential aminoacid for chlamydiae and 
host cells is sufficient to enable development of chlamydiae. It is believed that the 
persistence of chlamydiae is the result of competition between host and parasitic cells for L-
isoleucine. The treatment with cicloheximide, an inhibitor of host cell protein synthesis - 
stops the competition between the host cell and chlamydiae for L-isoleucine that remains 
available for bacterial protein synthesis. Chlamydiae induce synthesis of interferon that has 
been shown to inhibit pathogen growth in cell culture.  
3. Immunological aspects of acute and chronic Chlamydia infection  
The protective immunity for Chlamydia pneumoniae and Chlamydia trachomatis infections is 
quite similar. Innate immunity is of key importance in primary recognition of invading 
pathogens. Infected epithelial cells respond in similar, but not identical ways to different 
invading pathogens and the pathogens are capable of modifying the host cell response 
(Severin & Ossevarde, 2006). 
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Cell-mediated immunity and especially participation of type 1 Th cells are crucial for 
eradication or limitation of the infection at a culture negative stage. Primary infection 
induces development of antigen-specific immunity. Chlamydia pneumoniae is generally 
transmitted from person to person via the respiratory route (Kuo et al., 1995, Grayston, 
2002), where mechanical barriers and innate immune mechanisms comprise the first defense 
systems of the host. Epithelial cells lining the trachea and nasopharynx are the first cellular 
barriers against inhaled pathogens. Infection of airway epithelial cells can trigger a 
preliminary cascade of pro- and antiinflammatory immune reactions (secretion of IL-8, and 
expression of the epithelial adhesion molecule-1) that initiate drifting of polymorphonuclear 
neutrophils (PMN) and acute inflammation. Trachoma is the leading infectious cause of 
blindness. Eighty-five million children have active (inflammatory) trachoma, and about 7 
million people, mainly adults, are blind from late scarring sequelae (Thylefors et al., 1995).  
In trachoma, ocular Chlamydia trachomatis infection causes inflammatory changes in the 
conjunctiva, and repeated infections sometimes lead to fibrosis and scarring of the sub tarsal 
conjunctiva. The reasons for the heterogeneity in susceptibility to chlamydial infection and 
disease progression following a rather uniform bacterial exposure remain incompletely 
understood, but however, it has been postulated that the early secretion of pro-
inflammatory cytokines and chemokines by epithelial cells following Chlamydia trachomatis 
infection may initiate and sustain a chronic inflammatory process associated with pathology 
(Stephens, 2003).  
Natividad et al. (2009) tried to investigate how genetic variation detected in IL8 and CSF2 
(colony stimulating factor) could affect risk of trachoma: IL8, CSF2 and MMP9 (matrix-
metallo proteinase) are co-expressed in the Chlamydia trachomatis infected conjunctiva and 
these gene products could interact at the site of infection to augment and sustain 
inflammatory processes. MMP9 enhance the activity of IL8, whereas activation of 
neutrophils by IL-8 may trigger the release of pro-MMP9, creating a potential for a positive 
feedback loop. Similarly, CSF2 release by the infected epithelial cells may mediate the influx 
and activation of inflammatory cells at the site of infection. Secreted CSF2 may trigger 
MMP9 production by monocytes, which could act to enhance and sustain the pro-
inflammatory cascade initiated by CSF2.  
The onset of acquired antigen-specific immune responses depends on the speed of microbial 
dissemination from the initial site to local lymph nodes (Lipscomb et al., 1995). A 
preliminary pulmonary infection occurs in the alveoli, where the invading Chlamydia 
undergoes phagocytosis by dendritic cells (Prebeck et al., 2001) or alveolar macrophages 
(Nakajo et al., 1990; Redecke et al., 1998). The destruction of intracellular bacteria is 
dependent on the macrophage activation and mediated by reactive oxygen and nitrogen 
intermediates. 
Chlamydia can protect against the microbicidal systems of the activated macrophages by 
inhibiting the phagolysosomal fusion and replicating in a special nonacidic chlamydial 
inclusion (Mihaescu et al., 2009). The migration of some infected macrophages and dendritic 
cells to regional lymph nodes contributes significantly to the initiation of the antigen-specific 
immune response (Lipcomb et al., 1995) 
The acquired immune response, both humoral and cell-mediated in Chlamydia pneumoniae 






infection. Monocytes/macrophages and dendritic cells participate in the development of 
antigen-specific cell-mediated immunity by: (1) acting as antigen presenting cells (APC) and 
by (2) secretion of pro- IL-6, IL-1, IL-12) and antiinflammatory (IL-10, IL-13, cytokines, 
which activate other immune cells. In particular, the balance of IL-12 and IL-10 is crucial in 
regulating the development and functional characteristics of T cell responses (Surcel et al., 
2005). 
Chlamydial peptides processed by professional APC are further presented by MHC class II 
molecule to T CD4+ cells, although some chlamydial peptides are available also for MHC 
class I presentation. Activation of type 1 Th cell responses by IL-12 and IL-18 is considered 
the most important cytokine controlling chlamydiae infections, by regulating the cytotoxic T 
cells and by direct induction of nitric oxide synthase and the nitric oxide production in the 
macrophages as well as tryptophan depletion that inhibit chlamydial growth (Surcel et al., 
2005). Activation of a type 2 cytokine response is associated with increased susceptibility to 
Chlamydia trachomatis and Chlamydia pneumoniae infection in experimental animal models.  
Protective impact of T cells involves promotion of type 1 responses by activating other 
inflammatory cells, monocytes and macrophages, and cytotoxic T cells and B cells via 
cytokine secretion. CD4+ T cell activation generally dominates over CD8+ in in vitro and in 
vivo studies (Halme et al., 2000) especially in later stages of infection.  
In primary infection in healthy people, circulating lymphocytes respond equally to 
Chlamydia pneumoniae and Chlamydia trachomatis antigens, suggesting that conservative 
chlamydial structures dominate over the species-specific ones as targets for the cell-
mediated responses (Halme et al., 1997). The immune escape of chlamydiae within the host 
includes mechanisms for evasion of T cell recognition by interfering with the expression of 
MHC molecules. Chlamydia pneumoniae can suppress MHC class II expression on human 
monocytes (Airenne et al., 2002) or MHC class I expression on a monocytic cell line (Caspar-
Baughil et al., 2000). In this process, Chlamydia pneumoniae secretes a proteolytically active 
molecule (Fan et al., 2002) a homologue of chlamydial protease-like activity factor of 
Chlamydia trachomatis, which can degrade constitutive transcription factors RFX5 and USF-1 
molecules needed for antigen transcription during microbial infection (Zhong et al., 2001) . 
IL-10 by infected macrophages seems to inhibit the expression of MHC molecules (Caspar-
Banguil et al., 2000). 
Concerning the antibodies responses in chlamydiae infection, IgM response appears 2–3 
weeks after the first symptoms of the illness and IgG response after 6–8 weeks. IgA 
antibodies are only occasionally found during the primary infection but appear frequently 
in the reinfection. The main antigens triggering an antibody mediated response are LPS and 
HSP-60. The protective value of these antibodies is still to be established. 
Most of the times, especially in the infectious processes, immune responses are beneficial, 
having a role in eliminating pathogens. Sometimes, however, after the contact with some 
antigens (in particular molecular ones), activation of immune function is damaging and 
unfavorable for the host, causing two types of clinical manifestations: hypersensitivity and 
autoimmune diseases. Decreased immune system activity, generates a particular type of 
clinical manifestations generically known as immunodeficiencies. They can be congenital 
(primary) or acquired (secondary). 
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The state of hypersensitivity (HS) is a consequence of the fact that the primary 
immunization after the contact with the antigen and generation of immune effectors 
(antibodies and effector lymphocytes) do not give always a positive state, i.e. the resistance 
of the organism to an infection. Primary contact with the antigen creates sometimes a state 
of alert to the respective antigen, and at the second contact with the respective antigen, the 
human body responds by pathological hypersensitivity states, characterized by too high 
intensity or inappropriate immune response, which are the origin of tissue damage. The 
equivalent term commonly used for hypersensitivity is the allergy (allos, ergon,  greek = 
other energy). 
Autoimmunity is essentially an immune response against self antigens, which initiates the 
autoimmune conflict. One of the axioms of Immunology, that the host normal immune 
reactivity, does not produce antibodies against the body's own constituents, is frequently 
violated because the immune system turns against its own tissue components, disrupting 
the state of tolerance. Especially in the elderly, there are synthesized autoantibodies or 
autoreactive lymphocytes could occur (Lazar et al., 2005; Mihaescu et al., 2009). 
By extending its effects, the autoimmune conflict can lead to autoimmune diseases 
characterized by the proliferative expansion of lymphocytes reactive against self 
components and generated effectors (autoreactive cells and antibodies) (Mihaescu and 
Chifiriuc, 2009). There are diseases with autoimmune phenomena well expressed, but their 
primary etiology is unknown. Among the variate range of acute infections caused by 
Chlamydia pneumoniae (pharyngitis, bronchitis, pneoumonia), late complications (asthma, 
allergic rhinitis, heart disease, multiple sclerosis, Alzheimer's) could occur (Friedman et al., 
2004).  
Chlamydia could induce a local T cell immunosuppression and inflammatory response 
revealing a possible host-pathogen scenario that would support both persistence and 
inflammation. For example, Chlamydia pneumoniae could inhibit activated, but not 
nonactivated human T cell proliferation in a pathogen specific maner, heat sensitive, and 
multiplicity of infection dependent. The Chlamydia pneumoniae antiproliferative effect is 
linked to T cell death associated with caspase 1, 8, 9, and IL-1ǃ production, indicating that 
both apoptotic and proapoptotic cellular death pathways is activated after pathogen-T cell 
interactions (Olivares-Zavaleta et al., 2011).  
Although T-cell activation during acute Chlamydia pneumoniae infections has been described, 
little is known about the frequency or the role of the Chlamydia pneumoniae-specific memory 
T cells that reside in the human body after the resolution of the infection. The analysis of 
Chlamydia pneumoniae-induced T-cell responses in peripheral blood mononuclear cells 
showed that following short-term stimulation with Chlamydia pneumoniae, both gamma 
interferon (IFN-Ǆ)- and interleukin-2 (IL-2)-producing CD4 (+) T-cell responses could be 
detected in some PBMC culture from healthy individuals. Chlamydia pneumoniae-activated 
CD4(+) T cells expressed CD154, a marker for T-cell receptor-dependent activation, and 
displayed a phenotype of central memory T cells showing dominant IL-2 production but 
also IFN-gamma production.  
Interestingly, individuals with both IFNǄ and IL-2-producing responses showed 
significantly decreased immunoglobulin G reactivity toward Chlamydia pneumoniae RpoA 






compared to IgG reactivity of seropositive individuals with no T-cell response or CD4(+) T-
cell responses involving the production of a single cytokine (IFN-Ǆ or IL-2). Among 
seropositive individuals, the presence or the absence of dual IFN-Ǆ and IL-2-producing T-
cell responses was associated with distinct patterns of antibody responses toward 
persistence-associated Chlamydia pneumoniae antigens. 
4. Chlamydia pneumoniae infection and chronic diseases with 
immunopathological background 
There are many seroepidemiological, pathological, animal, immunological and antibiotic 
treatment studies demonstrating the role of chlamydial infection in atherosclerosis. EBs of 
Chlamydia pneumoniae is internalized by endocytosis in the alveolar macrophages, and 
differentiates in RBs, which are multiplying. Circulating monocytes are infected and the 
appearance of chlamydial inclusions in the vascular endothelium modulates their adhesion. 
The adhered macrophages migrate later in the intimate of blood vessels, where they cause 
infection of other cell types, including arterial macrophages, which will start to accumulate 
LDL (low density lipoproteins), getting a "foamy" aspect because of the stored cholesterol. 
Under nonatherogenic conditions, LDL uptake causes the transcriptional downregulation of 
its receptor. Scavenger receptors, however, may bypass this control by allowing the 
endocytosis of modified LDL. Chlamydia pneumoniae heat shock protein–60 (cHsp60) was 
found to induce cellular oxidation of LDL cholesterol, while Chlamydia pneumoniae LPS as 
the antigen that could enhance LDL cholesterol uptake and downregulate cholesterol efflux 
in monocytes and macrophages (Kalayoglu et al., 2002; Higgins, 2003). 
Smooth muscle fibers will also be infected by the EBs and will proliferate, and infected 
endothelial cells will secrete a number of cytokines, which will ultimately lead to the 
destabilization of the ateromatous plaque and thrombus formation, with an increased risk of 
myocardial infarction. 
Currently, serological methods could fail in detecting chronic or persistent Chlamydia 
pneumoniae infection and other blood markers such as Chlamydia pneumoniae immune 
complexes and circulating leukocytes, e.g. macrophages with detectable Chlamydia 
pneumoniae DNA and mRNA as markers of underlying infection are needed (Ngeh et al., 
2002; Ngeh & Gupta, 2002). The association of some inflammatory markers such as C-
reactive protein (CRP) with Chlamydia pneumoniae serology has indicated the existence of 
some correlations between “infectious” and “inflammatory” burdens and atherosclerosis 
(Leinonen & Saikku, 2002). Cytokines released by these immune cells, such as IL-6, induce 
acute phase response proteins, and elevated CRP levels, (a marker for atherosclerosis) are an 
indication of chronic inflammation. The inflammatory nature of the early atheroma causes 
modifications to LDL, which allow the molecule to bypass the usual regulatory mechanisms 
for entry into cells, thus facilitating foamy cell formation. Furthermore, the effect of 
inflammation on endothelial cells allows for greater arterial permeability to LDL and 
increased adhesion molecule expression and diapedesis of leukocytes.  
The presence of Chlamydia pneumoniae was evidenced by different methods including 
immunocytochemistry, PCR, in situ hybridization and electron microscopy not only in 
coronary arteries, but also in cerebral, carotid, internal mammary, pulmonary, aorta, renal, 
iliac, femoral, and popliteal arteries, and occluded bypass grafts, obtained from postmortem 
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and surgical atheromatous tissues (Leinonen & Saikku, 2002; Ngeh et al., 2002, Ngeh & 
Gupta, 2002, Rassu et al., 2001). However, it must be taken into account that Chlamydia 
pneumoniae can also be detected in about 10% of noncardiovascular and granulomatous 
tissues, showing a nonspecific, ubiquitous distribution in the human body (Ngeh et al., 2002, 
Ngeh & Gupta, 2002). 
Animal models have shown that Chlamydia pneumoniae infection could initiate and accelerate 
atherosclerotic process. Repeated Chlamydia pneumoniae infection in genetically modified 
mouse such as ApoE-deficient mouse known to develop atherosclerosis in the absence of a 
fatty diet in has been shown to accelerate atherosclerotic lesion progression by specifically 
increasing the T lymphocyte influx in the atherosclerotic plaques and accelerating the 
formation of more advanced atherosclerotic lesions (Ezzahiri et al., 2002). 
The exact pathogenesis of multiple sclerosis (MS), the most common demyelinating disease 
of the central nervous system (CNS) (Noseworthy, 1999; Nosewrothy et al., 2002) remains 
unknown, but current hypothesis are reffering to an autoimmune background that may be 
influenced by an infectious process. Chlamydia pneumoniae has been found to be associated 
with the rapidly progressive multiple sclerosis (Sriram et al., 1998), or relapsing multiple 
sclerosis, markedly improved after targeted antimicrobial therapy (Sriram et al., 1999) 
The association between Chlamydia pneumoniae and multiple sclerosis was demonstrated in 
experimental pathogenesis, showing that after intraperitoneal inoculation of mice with 
Chlamydia pneumoniae, following immunization with neural antigens, an increased severity 
of experimental allergic encephalitis (EAE), an animal model of multiple sclerosis was 
observed. An attenuation of EAE following therapy with the antimicrobial agent 
fluorphenicol (Du et al., 2002) was observed. Persistence of Chlamydia pneumoniae in the CNS 
is likely to provide an environment that can lead to the activation of autoreactive T cells and 
contribute to the pathogenesis of a chronic disease such as multiple sclerosis (Stratton & 
Sriram, 2004). 
Alzheimer’s disease (AD) is a progressive neurodegenerative condition that accounts for the 
most common and severe form of dementia in the elderly The pathology observed in the 
brain includes neuritic senile plaques, neurofibrillary tangles, neuropil threads  and deposits 
of cerebrovascular amyloid  (Balin et al., 2005). 
Balin et al. (1998) demonstrated by polymerase chain reaction (PCR) that the DNA of 
Chlamydia pneumoniae was present in 90% of postmortem brain samples examined from 
sporadic AD.). Immunohistochemistry revealed the presence of Chlamydia pneumoniae 
antigens in perivascular macrophages, microglia, and astroglial cells in areas of the temporal 
cortices, hippocampus, parietal cortex, and prefrontal cortex in AD patients, but not in 
control samples. Electron microscopy revealed chlamydial inclusions that contained 
elementary (EB) and reticulate (RB) bodies. Microglia responds to insult with the production 
of proinflammatory cytokines, and the generation of reactive oxygen species and other 
products (Simpson et al., 1998). Monocytes acutely or chronically in vitro infected with 
Chlamydia pneumoniae appeared to increase the expression of amyloid precursor protein as 
well as the increased breakdown of the precursor into fragments that contained 1–40 







The way by which Chlamydia pneumoniae croos the blood–brain barrier to reach the central 
nervous system is probably represented by the circulating monocytes infected with 
Chlamydia pneumoniae (Boman et al., 1998; Airenne et al., 1999). The transmigration is 
facilitated by the increased surface expression of the surface adhesins on the endothelial 
cells and the integrins on the monocytes. Chlamydia pneumoniae may reach into the central 
nervous system through the the olfactory neuroepithelium of the nasal olfactory system, in 
direct contact with the infected epithelial cells.  
Reactive arthritis is a sterile immune-mediated pathogenesis process of the joint that follows 
bacterial infection of either the gastrointestinal or urogenital system (Whittum-Hudson et 
al., 2004). Chronic reactive arthritis associated with chlamydial infection is manifested with 
activation of TH1/TH2 CD4+ cells and macrophages at sites of inflammation (Carter & 
Dutton, 1996). In addition, at sites of chlamydial infections, proinflammatory cytokines IL-6, 
and TH1-associated cytokines and IL-12 have been identified (Mosmann & Coffman, 1989). 
It is not clear whether chlamydial infection elicits an inflammatory response because of 
upregulated cytokine production in infected or neighbouring cells, or if the immune 
response to infected cells drives the inflammatory response via influx of cytokine-producing 
lymphocytes and macrophages. Nonetheless, synovial materials have been studied for the 
panel of cytokines present in Chlamydia trachomatis- and Chlamydia pneumoniae–induced 
inflammatory arthritis. After development of inflammation, Th1/Th2 CD4+ cells, as well as 
CD8+ cells and macrophages, have been detected in synovial fluid (Simon et al., 1993). 
Many studies have indicated that, in patient materials from individuals with early disease, 
proinflammatory cytokines such as IL-12 and are prominent (Kotake et al., 1999; Simon et 
al., 1993). In Chlamydia trachomatis–infected joint tissues from chronic reactive arthritis 
patients, IL-10, IL-8, IL-15 and MCP-1t (Gérard et al., 2002) have been identified. In the same 
study, it was shown that in synovial tissue samples from arthritis patients chronically 
infected at that site with Chlamydia pneumoniae, essentially only mRNA encoding IL-8, and 
RANTES were present.  
Acute Chlamydia pneumoniae infection can cause acute bronchitis and pneumonia, and lower 
respiratory tract illnesses can develop into asthma and chronic bronchitis. Chronic 
Chlamydia pneumoniae infection has also been associated with a wide variety of chronic 
upper-airway illnesses, as well as with acute and chronic lower-airway conditions including 
acute bronchitis, asthma and COPD.  
Chlamydia pneumoniae infection could have three distinguishable causal effects: acute asthma 
exacerbations (Allegra et al., 1994, Clementsen et al., 2002); promoting asthma severity (von 
Hertzen, 2002); or initiate asthma (Hahn et al., 2005).  
A significant association between asthma and Chlamydia pneumoniae-specific IgA (Hahn et 
al., 2000, Genkay et al., 2001, Falk et al., 2002) and also with chlamydial heat shock protein–
60 (Hsp60) antibodies (Roblin et al., 2000, Huttinen et al., 2001) has been reported by 
different authors. 
It is already established that the inflammatory processes of chlamydial pathogenesis are 
elicited by infected host cells and are necessary and sufficient to account for chronic and 
intense inflammation and the promotion of cellular proliferation, tissue remodelling and 
scarring, the ultimate cause of disease sequelae (Stephens, 2003).  
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One mechanism by which infection can initiate autoimmune disease is molecular mimicry, 
the phenomenon of protein products from dissimilar genes sharing similar structures that 
elicit an immune response to both self and microbial proteins. The strongest cases for 
molecular mimicry seem to have been made for chlamydial heat shock proteins 60, the DNA 
primase of Chlamydia trachomatis, and chlamydial OmcB proteins (Bachmaier & Penninger, 
2005). So, the HSPs are expressed by cells within atherosclerotic plaques, and anti-HSP 
antibodies serum titres have been reported to be positively related to future risk of coronary 
heart disease. On the other hand, purified anti-HSP antibodies recognise and mediate the 
lysis of stressed human endothelial cells and macrophages in vitro and future immunisation 
with HSP exacerbates atherosclerosis in experimental animal models. Taking into account 
that some human vaccines, such as BCG, contain HSPs, hence although vaccination 
programmes are vital for maintaining ‘herd’ immunity and the prevention of serious 
infectious disease, they may leave a legacy of increased susceptibility to atherosclerosis 
(Lamb et al., 2003).  
To investigate the conditions under which autoimmune responses can be generated against 
self hsp60, Yi et al., (1997) demonstrated that autoimmune responses characterized by strong 
T-cell proliferation and high titers of antibody to self hsp60 are induced only by concurrent 
immunization with mouse and chlamydial hsp60. They observed that switches in cytokine 
production patterns may mediate the pathogenesis of hsp60-associated Chlamydia 
trachomatis immunopathology. Immunization with mouse hsp60 alone induced lymphocytes 
that secreted high levels of interleukin-10 (IL-10) but did not proliferate in response to in 
vitro stimulation with mouse hsp60. On the other hand, co-immunization with mouse and 
chlamydial hsp60s induced lymphocytes that proliferated strongly in response to mouse 
hsp60, secreted 6-fold less IL-10, and exhibited a 12-fold increase in the ratio of IFNǄ /IL-10 
production (Yi et al., 1997). The development of infertility is reported due to enhanced 
immune responses to Chlamydia trachomatis (Debattista et al., 2003), and cHSP60 and cHSP10 
antibodies seem to perform well in predicting tubal factor infertility (Spandorfer et al., 1999; 
LaVerda et al., 2000; den Hartog et al., 2005; Dadamessi et al., 2005; Linhares & Witkin, 
2010). During Chlamydia infection a crucial for controlling the duration of infection and 
subsequent tubal pathology have Th1/Th2 responses: Th1 cells produce IFN-Ǆ that 
promotes the destruction of Chlamydia (Beatty et al., 1993), but can also promote 
inflammatory damage and fibrosis (Rottenberg et al., 2002) whereas Th2 cells produce IL-4, 
IL-5, and IL-13 believed to be critical for defense against extracellular pathogens. The 
production of TNF-ǂ and IL-10 was examined because their levels have been reported to be 
high in cervical secretions of Chlamydia trachomatis infected infertile women (Reddy et al., 
2004). In order to elucidate the actual role in the cause of infertility, Srivastava et al., (2008) 
studied the specific cytokine responses of mononuclear cells from the infectious site to 
cHSP60 and cHSP10. Exposure to chlamydial heat shock proteins (cHSP60 and cHSP10) 
could significantly affect mucosal immune function by increasing the release of IFN-Ǆ, IL-10 
and TNF-alpha by cervical mononuclear cells, much more in infertile group as compared to 
fertile group. 
5. Conclusion  
Chlamydia infection has excited considerable attention in the last time research, not only as a 






chronic diseases. The true significance of Chlamydia infection in the development of chronic 
manifestations still remains puzzling. The factors that drive immune responses to 
pathogenic species, the role of host genetic background, HLA molecules and cytokine gene 
polymorphism, environmental and epidemiological factors, mixed infections, and species or 
dose of the infecting agent probably all interact in a final balance of the immune defense 
mechanisms. Chlamydial infections in vivo typically result in chronic inflammation 
characterized cellularly by the presence of activated monocytes and macrophages and by 
the secretion of Th-1/Th-2 cytokines, which could lead to the dysregulation of the immune 
response resulting in autoimmune diseases. Understanding the mechanisms by which 
chlamydial infections, especially chronic and persistent ones interfere with the host immune 
defence system is necessary to develop better therapies to treat and possibly even prevent 
Chlamydia associated diseases. However, the early identification and treatment of genital 
chlamydial infection of women, of eye infection in children and of Chlamydia pneumoniae in 
chronic airways disease will be important to prevent the development of chronic sequelae, 
with immunological basis. 
6. Acknowledgment 
Acknowledgement: to the ANCS bilateral project Romania –Republic of Moldavia, no 
423/04.06.2010 and National Project PN2 42119/2008 and PN2 42150/2008. 
7. References  
Airenne, S.; Kinnunen, A.; Leinonen, M.; Saikku, P. & Surcel, H.M. (2002). Secretion of IL-10 
and IL-12 in Chlamydia pneumoniae infected human monocytes, presented at 
Chlamydial Infections Proceedings of the Tenth International Symposium on Human 
Chlamydial Infections, Antalya, Turkey. 
Allegra‚ L.; Blasi‚ F.; Centanni‚ S.; Cosentini‚ R.; Denti‚ F.; Raccanelli‚ R.; Tarsia‚ P. & Valenti‚ 
V. (1994). Acute exacerbations of asthma in adults: Role of Chlamydia pneumoniae 
infection‚ Eur. Respir.J. Vol. 7, pp. 2165–2168. 
Airenne, S.; Surcel, H.M.; Alakarppa, H.; Laitinen, K.; Paavonen, J.; Saikku, P. & Laurila, A. 
(1999). Chlamydia pneumoniae infection in human monocytes, Infect. Immun. Vol. 67, 
pp. 1445–1449. [published erratum appears in Infect. Immun. (1999) 67:6716].  
Bachmaier, K. & Penninger, J.M. (2005). Chlamydia and antigenic mimicry. Curr Top 
Microbiol Immunol. Vol. 296, pp.153-63. 
Balin, B.J.; Hammond, C.J.; Little, C.S.; Macintyre, A. & Appelt, D.M. (2005). Chlamydia 
pneumoniae in the Pathogenesis of Alzheimer’s Disease, In: Chlamydia 
pneumoniae: Infection and disease. Friedman H., Yamamoto Y, Bendinelli M. pp. 
211-226, Ed. Kluwer Academic Publishers, ISBN 0-306-48487-0, New York. 
Balin, B.J.; Gerard, H.C.; Arking, E.J.; Appelt, D.M.; Branigan, P.J.; Abrams, J.T.; Whittum-
Hudson, J.A. & Hudson, A.P. (1998). Identification and localization of Chlamydia 
pneumoniae in the Alzheimer’s brain, Med. Microbiol. Immunol. Vol. 187, pp. 23–42. 
Barnes, R.C. (1990). Infections Caused by Chlamydia trachomatis, In Sexually Transmitted 
Diseases. Morse. SA, Moreland AA, Thompson SE, eds, J.B. Lippincott. Philadelphia 
Beatty, W.L.; Byrne, G.I. & Morrison, R.P. (1993). Morphologic and antigenic 
characterization of interferon gamma-mediated persistent Chlamydia trachomatis 
infection in vitro. Proc Natl Acad Sci USA, Vol. 90, pp. 3998-4002. 
www.intechopen.com
 
Host Immune Response to Chlamydia Infection 
 
87 
Boman, J.; Soderberg, S.; Forsberg, J.; Birgander, L.S.; Allard, A.; Persson, K.; Jidell, E.; 
Kumlin, U.; Juto, P.; Waldenstrom, A. & Wadell, G. (1998). High prevalence of 
Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with 
cardiovascular disease and in middle-aged blood donors, J. Infect. Dis. Vol. 178, pp. 
274–277. 
Campbell, L.A. & Kuo, C.C. (2004). Chlamydia pneumoniae — an infectious risk factor for 
atherosclerosis? Nature Reviews Microbiology, Vol. 2, pp. 23-32. 
Carter, L.L. & Dutton, R. W. (1996). Type 1 and Type 2: A fundamental dichotomy for all T-
cell subsets, Curr. Opin. Immunol., Vol. 8, pp. 336–342. 
Caspar-Bauguil, S.; Puissant, B.; Nazzal, D.; Lefevre, J.C.; Thomsen, M.; Salvayre, R. & 
Benoist, H. (2000). Chlamydia pneumoniae induces interleukin-10 production that 
downregulates major histocompatibility complex class I expression, J. Infect. Dis. 
Vol. 182, No. 5, pp. 1394-1401. 
Clementsen‚ P.; Permin‚ H. & Norn‚ S. (2002). Chlamydia pneumoniae infection and its role in 
asthma and chronic obstructive pulmonary disease‚ J. Invest. Allergol. Clin. Immunol. 
Vol. 12, pp. 73–79. 
Dadamessi, I.; Eb, F. & Betsou. F. (2005). Combined detection of Chlamydia trachomatis 
specific-antibodies against the 10 and 60-kDa heat shock proteins as a diagnostic 
tool for tubal factor infertility: Results from a case-control study in Cameroon. 
FEMS Immunol Med Microbiol, Vol. 45, pp. 31-35.  
Debattista, J.; Timms, P.; Allan, J. & Allan, J. (2003). Immunopathogenesis of chlamydia 
trachomatis infections in women. Fertil Steril. Vol. 79, No. 6, pp. 1273-1287. 
den Hartog JE, Land JA, Stassen FR, Kessels AG, Bruggeman CA: Serological markers of 
persistent Chlamydia trachomatis infections in women with tubal factor subfertility. 
Hum Reprod 2005, 20:986-990.Debattista, J.; Timms, P.; Allan, J. & Allan, J. (2003). 
Immunopathogenesis of Chlamydia trachomatis infections in women. Fertil Steril. 
Vol. 79, pp. 1273-1287.  
Du, C.; Yi-Yao, S.; Rose, A. & Sriram, S. (2002). Chlamydia pneumoniae infection of the central 
nervous system worsens EAE, J. Exp. Med., Vol. 196, pp. 1639–1644. 
Ezzahiri, R.; Nelissen-Vrancken, H.J.M.G.; Kurvers, H.A.J.M.; Stassen, F.R.M.; Vliegen, I.; 
Grauls, G.E.L.M.; van Pul, M.M.L.; Kitslaar, P.J.E.H.M. & Bruggeman, C.A. (2002). 
Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of 
complex atherosclerotic lesions in Apo E3-Leiden mice, Cardiovasc. Res. Vol. 56, pp. 
269–276. 
Falck‚ G.; Gnarpe, J.; Hansson‚ L.O.; Svärdsudd‚ K. & Gnarpe‚ H. (2002). Comparison of 
individuals with and without specific IgA antibodies to Chlamydia pneumoniae. 
Respiratory morbidity and the metabolic syndrome‚ Chest, Vol. 122, pp. 1587–1593. 
Fan, P.; Dong, F.; Huang, Y. & Zhong, G. (2002). Chlamydia pneumoniae secretion of a 
protease-like activity factor for degrading host cell transcription factors is required 
for major histocompatibility complex antigen expression, Infect. Immun. Vol. 70, No. 
3, pp. 345-349.  
Gencay‚ M.; Rüdiger‚ J.J.; Tamm‚ M.; Solér‚ M.; Perruchoud‚ A.P. & Roth‚ M. (2001). 
Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma‚ 
Am.J.Respir. Crit. Care Med. Vol. 163, pp. 1097–1100. 
Gérard, H.C.; Wang, Z.; Whittum-Hudson, J.A.; El-Gabalawy, H.; Goldbach-Mansky, R.; 
Bardin, T.; Schumacher, H.R. & Hudson, A.P. (2002). Cytokine and chemokine 
mRNA produced in synovial tissue chronically infected with Chlamydia 






Grayston, J.T. (2002) Background and current knowledge of Chlamydia pneumoniae and 
atherosclerosis, J. Infect. Dis. Vol. 181, S3, pp. S402-S410. 
Hahn‚ D.L.; Peeling‚ R.W.; Dillon‚ E.; McDonald‚ R. & Saikku‚ P. (2000). Serologic markers 
for Chlamydia pneumoniae in asthma‚ Ann. Allergy Asthma Immunol. Vol. 84, No. 2, 
227–233. 
Hahn D.L. (2005). Role of Chlamydia pneumonia as an Inducer of Asthma. In Friedman H., 
Yamamoto Y, Bendinelli M. ed. Infectious agents and pathogenesis. Kluwer 
Academic/Plenum Publishers, pp. 1-10. 
Halme, S.; Latvala, J.; Karttunen, R.; Palatsi, I.; Saikku, P. & Surcel, H.M. (2000). Cell-
mediated immune response during primary Chlamydia pneumoniae infection, Infect. 
Immun. Vol. 68, No. 12, pp. 7156-7158. 
Halme, S.; Syrjälä, H.; Bloigu, A.; Saikku, P.; Leinonen, M.; Airaksinen,J. & Surcel, H.M. 
(1997). Lymphocyte responses to Chlamydia antigens in patients with coronary heart 
disease, Eur. Heart J. Vol. 18, No. 7, pp. 1095-1101. 
Hatch, T.P. (1996). Disulfide Cross-Linked Envelope Proteins: the Functional Equivalent of 
Peptidoglycan in Chlamydia? J. Bacteriol., Vol. 178, No. 1, pp. 1-5. 
Higgins, J.P. (2003). Chlamydia pneumoniae and coronary artery disease: The antibiotic trials, 
Mayo Clin. Proc. Vol. 78, No. 3, pp. 321–332. 
Kalayoglu, M.V.; Libby, P. & Byrne, G.I. (2002). Chlamydia pneumoniae as an emerging risk 
factor in cardiovascular disease, JAMA Vol. 288, pp. 2724–2731. 
Kotake, S.; Schumacher, H.R.; Arayssi, T.K.; Gérard, H.C.; Branigan, P.J.; Hudson, A.P.; 
Yarboro, C.H.; Klippel, J.H. & Wilder, R.L. (1999). IL-10, and IL-12 p40 gene 
expression in synovial tissues from patients with recent-onset Chlamydia-associated 
arthritis, Infect. Immun. Vol. 67, pp. 2682–2686. 
Kuo, C.C.; Jackson, L.A.; Campbell, L.A. & Grayston, J.T. (1995). Chlamydia pneumoniae 
(TWAR), Clin. Microbiol. Rev. Vol. 8, No. 4, pp. 451-461. 
LaVerda, D.; Albanese, L.N.; Ruther, P.E.; Morrison, S.G.; Morrison, R.P.; Ault, K.A. & 
Byrne, G.I. (2000). Seroreactivity to Chlamydia trachomatis Hsp10 correlates with 
severity of human genital tract disease. Infect Immun, Vol. 68, No. 1, pp. 303-309. 
Lamb DJ, El-Sankary W, Ferns GA. 2003 Molecular mimicry in atherosclerosis: a role for 
heat shock proteins in immunisation. Atherosclerosis. Vol. 167, No. 2, pp. 177-85. 
Lazar, V.; Balotescu, M.C.; Cernat, R.; Bulai, D. & Stewart-Tull, D. (2005). Imunobiologie, Ed. 
Univ. din Bucuresti, Bucharest, 250 p. ISBN-973-73-7124-0 
Leinonen, M. & Saikku, P. (2002). Evidence for infectious agents in cardiovascular disease 
and atherosclerosis, Lancet Infect. Dis. Vol. 2, No. 2, pp. 11–17. 
Linhares, I.M. & Witkin, S.S. (2010). Immunopathogenic consequences of Chlamydia 
trachomatis 60 kDa heat shock protein expression in the female reproductive tract. 
Cell Stress Chaperones. Vol. 15, No. 5, pp. 467-473.  
Lipscomb, M.F.; Bice, D.E.; Lyons, C.R.; Schuyler, M.R. & Wilkes, D. (1995). The regulation 
of pulmonary immunity, Adv. Immunol. Vol. 59, pp. 369-455.  
Madigan, M.; Martinko, J.; Parker, J. (2008). In Brock's Biology of Microorganisms. (12th 
Edition), ISBN 0132324601, New Jersey: Prentice Hall. 
Matsumoto, A.; Bessho, H.; Uehira, K. & Suda, T. (1991). Morphological studies of the 
association of mitochondria with chlamydial inclusions and the fusion of 
chlamydial inclusions, J. Electron Microsc. Vol. 40, No. 5, pp. 356–363. 
Mihăescu, G. & Chifiriuc, M.C. (2009). Organizarea sistemului imunitar la vertebrate, 2009, 
in vol.  Imunogenetică şi Oncogenetică, Ed. Academia Românǎ. 




Host Immune Response to Chlamydia Infection 
 
89 
Mosmann, T. R. & Coffman, R. L., (1989). TH1 and TH2 cells: Different patterns of 
lymphokine secretion lead to different functional properties, Annu. Rev. Immunol. 
Vol. 7, pp. 145–173. 
Nakajo, M.N.; Roblin, P.M.; Hammerschlag, M.R.; Smith, P. & Nowakowski, M. (1990). 
Chlamydicidal activity of human alveolar macrophages, Infect. Immun. Vol. 58, No. 
11, pp. 3640-3644. 
Natividad, A.; Hull, J.; Luoni, G.; Holland, M.; Rockett, K.; Joof, H.; Burton, M.; Mabey, D.; 
Kwiatkowski, D.& Bailey, R. (2009). Innate immunity in ocular Chlamydia 
trachomatis infection: contribution of IL8 and CSF2 gene variants to risk of 
trachomatous scarring in Gambians. MC Med Genet. Vol. 10, pp.138. 
doi:10.1186/1471-2350-10-138 
Ngeh.J.; Anand, V. & Gupta, S. (2002). Chlamydia pneumoniae and atherosclerosis-what we 
know and what we don’t, Clin. Microbiol. Infect. Vol. 8, No. 1, pp. 2–13. 
Ngeh, J. & Gupta, S. (2002). Inflammation and infection in coronary artery disease, in: Cardiology: 
Current Perspectives (G.Jackson, ed.), Martin Dunitz Ltd., London., 125–144. 
Noseworthy, J.H. (1999). Progress in determining the causes and treatment of multiple 
sclerosis, Nature, Vol. 399, 6738 Suppl., pp. A40–A47. 
Noseworthy, J.H.; Lucchinetti, C.; Rodriguez, M. & Weinshenker, B.G. (2000). Multiple 
Sclerosis, New. Eng.J. Med., Vol. 343, No. 13, pp. 938–946. 
Olivares-Zavaleta, N.; Carmody, A.; Messer, R.; Whitmire, W.M. & Caldwell, H.D. (2011). 
Chlamydia pneumoniae inhibits activated human T lymphocyte proliferation by 
the induction of apoptotic and pyroptotic pathways. J Immunol. Vol. 186, No. 12, 
pp. 7120-7126. 
Prebeck, S.; Kirschning, C.; Durr, S.; da Costa, C.; Donath, B.; Brand, K.; Redecke, V.; 
Wagner, H. & Miethke, T. (2001). Predominant role of toll-like receptor 2 versus 4 
in Chlamydia pneumoniae–induced activation of dendritic cells, J. Immunol. Vol. 167, 
No. 6, 3316-3323. 
Rassu, M.; Cazzavillan, S.; Scagnelli, M.; Peron, A.; Bevilacqua, P. A.; Facco, M.; Bertoloni, 
G.; Lauro, F. M.; Zambello, R. & Bonoldi, E. (2001). Demonstration of Chlamydia 
pneumoniae in atherosclerotic arteries from various vascular regions, Atherosclerosis, 
Vol. 158, No. 1, pp.73–79. 
Reddy, B.S.; Rastogi, S.; Das, B.; Salhan, S.; Verma, S. & Mittal, A. (2004). Cytokine expression 
pattern in the genital tract of Chlamydia trachomatis positive infertile women – 
implication for T-cell responses. Clin Exp Immunol, Vol. 137, No. 3, pp. 552-558. 
Redecke, V.; Dalhoff, K.; Bohnet, S.; Braun, J. & Maass, M. (1998). Interaction of Chlamydia 
pneumoniae and human alveolar macrophages: Infection and inflammatory 
response, Am. J. Resp. Cell. Mol. Biol. Vol. 19, No. 5, pp. 721-727.  
Rottenberg, M.E.; Gigliotti-Rothfuchs, A. & Wigzell, H. (2002). The role of IFN-gamma in the 
outcome of chlamydial infection. Curr Opin Immunol, Vol. 14, pp. 444-451. 
Roblin‚ P.M.; Witkin‚ S.S.; Weiss‚ S.M.; Gelling‚ M. & Hammerschlag‚ M.R. (2000). Immune 
response to Chlamydia pneumoniae in patients with asthma: Role of heat shock 
proteins (HSPs)‚ in: Proceedings: Fourth Meeting of the European Society for Chlamydia 
Research‚ Helsinki‚ Finland‚ Esculapio‚ Bologna‚ Italy‚ p. 209. 
Severin, J.A. & Ossewaarde J.M. (2006) Innate immunity in defense against Chlamydia 
trachomatis infections. Drugs Today (Barc). Vo. 42, Suppl A:75-81. 
Shirai, M.; Hirakawa, H.; Kimoto, M.; Tabuchi, M.; Kishi, F.; Ouchi, K.; Shiba, T.; Ishii, K.; 
Hattori, S.; Kuhara, S. & Nakazawa, T. (2000). Comparison of whole genome 
sequencesof Chlamydia pneumoniae J 138 from Japan and CWL 029 from USA, 






Simon, A.K.; Seipelt, E.; Wu, P.; Wenzel, B.; Braun, J. & Sieper, J. (1993). Analysis of cytokine 
profiles in synovial T cell clones from chlamydial reactive arthritis patients: 
Predominance of the Th1 subset, Clin. Exp. Immunol. Vol. 94, pp. 122–126. 
Simpson, J.E.; Newcombe, J.; Cuzner, M.L. & Woodroofe, M.N. (1998). Expression of monocyte 
chemoattractant protein-1 and other beta-chemokines by resident glia and 
inflammatory cells in multiple sclerosis lesions, J. Neuroimmunol.Vol. 84, pp. 238–249. 
Spandorfer, S.D.; Neuer, A.; LaVerda, D.; Byrne, G.; Liu, H.C.; Rosenwaks, Z. & Witkin, S.S. 
(1999). Previously undetected Chlamydia trachomatis infection, immunity to heat 
shock proteins and tubal occlusion in women undergoing in-vitro fertilization. 
Hum Reprod, Vol. 14, No. 1, pp. 60-64.  
Sriram, S.; Mitchell, W. & Stratton, C. (1998). Multiple sclerosis associated with Chlamydia 
pneumoniae infection of the CNS, Neurology, Vol. 50, No. 2, pp. 571–572. 
Sriram, S.; Stratton, C.W.; Yao, S.; Tharp, A.; Ding, L.; Bannan, J.D. & Mitchell, W.M. (1999). 
C. pneumoniae infection of the CNS in MS, Ann. Neurol. Vol. 46, No. 1, pp. 6–14. 
Srivastava, P.; Jha, R.; Bas, S.; Salhan, S. & Mittal, A. (2008). In infertile women, cells from 
Chlamydia trachomatis infected sites release higher levels of interferon-gamma, 
interleukin-10 and tumor necrosis factor-alpha upon heat-shock-protein 
stimulation than fertile women. Reprod Biol Endocrinol. Vol. 6, pp. 20, 
doi:10.1186/1477-7827-6-20.  
Stephens RS. (2003). The cellular paradigm of chlamydial pathogenesis. Trends Microbiol. 
Vol. 11, No. 1, pp. 44-51. 
Stratton, C.W. & Sriram, S. (2005). Chlamydia pneumoniae as a candidate pathogen in multiple 
sclerosis. Chlamydia pneumoniae: Infection and disease. In: Chlamydia pneumoniae: 
Infection and disease. Friedman H., Yamamoto Y, Bendinelli M. pp. 199-210, Ed. 
Kluwer Academic Publishers, ISBN 0-306-48487-0, New York. 
Surcel H.M. (2005). Chlamydia pneumoniae Infection and Diseases: Immunity to Chlamydia 
Pneumoniae, In: Chlamydia pneumoniae: Infection and disease. Friedman H., 
Yamamoto Y, Bendinelli M. pp. 81-98, Ed. Kluwer Academic Publishers, ISBN 0-
306-48487-0, New York. 
Thylefors, B.; Negrel, A.D.; Pararajasegaram, R. & Dadzie K.Y. (1995). Global data on 
blindness. Bull World Health Organ, Vol. 73, No. 1, pp. 115-121.  
Yi, Y.; Yang, X. & Brunham, R.C. (1997). Autoimmunity to heat shock protein 60 and antigen-
specific production of interleukin-10. Infect Immun. Vol. 65, No. 5, pp. 1669-74. 
von Hertzen‚ L.‚ Vasankari‚ T.‚ Liippo‚ K.‚ Wahlström‚ E. & Puolakkainen‚ M. (2002). Chlamydia 
pneumoniae and severity of asthma‚ Scand. J. Infect. Dis. Vol. 34, No. 1, pp. 22–27. 
Whittum-Hudson, J.A.; Schumacher, H.R. & Hudson A.P. (2005). Chlamydia pneumoniae and 
Inflammatory Arthritis, In: Chlamydia pneumoniae: Infection and disease. 
Friedman H., Yamamoto Y, Bendinelli M. pp. 227-238, Ed. Kluwer Academic 
Publishers, ISBN 0-306-48487-0, New York. 
Zhong, G.; Fan, P.; Ji, H.; Dong, F. & Huang, Y. (2001). Identification of a chlamydial 
protease-like activity factor responsible for the degradation of host transcription 
factors, J. Exp. Med. Vol. 193, No. 8, pp. 935-942. 
www.intechopen.com
Chlamydia
Edited by Prof. Mihai Mares
ISBN 978-953-51-0470-4
Hard cover, 358 pages
Publisher Intech
Published online 30, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Nowadays, Chlamydia still represents a redoubtable pathogen. Among its consequences, the blindness in
children and severe impairment of reproductive health in adults are the most mutilating. Worldwide, it is
estimated that six million of people suffer from post-trachoma blindness and almost 90 million become sexually
infected each year. Due to its silent evolution and sexually transmission, the chlamydial infection can occur in
anyone. The book “Chlamydia - A Multifaceted Pathogen” contains an updated review of all-important issues
concerning the chlamydial infection. It comprises 18 chapters grouped in four major parts dealing with etiology
and pathogenicity, clinical aspects, diagnosis and prevention. The new molecular data about the pathogenicity
and the exhaustive presentation of clinical findings bring novelty to the book and improve our knowledge about
Chlamydia induced diseases.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Chifiriuc Mariana Carmen, Socolov Demetra, Moshin Veaceslav, Lazar Veronica, Mihaescu Grigore and Bleotu
Coralia (2012). Host Immune Response to Chlamydia Infection, Chlamydia, Prof. Mihai Mares (Ed.), ISBN:
978-953-51-0470-4, InTech, Available from: http://www.intechopen.com/books/chlamydia/host-immune-
response-to-chlamydia-infection
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
